EZR and esophageal squamous cell carcinoma: The results showed that the number of migrated and invaded cells was significantly lower in the sh-Ezrin group than that in the KYSE150 group (Figure 4d, P < 0.05), suggesting that Ezrin can promote ESCC metastasis and invasion and may be a therapeutic target to prevent ESCC metastasis.